US4108983A - Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors - Google Patents
Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors Download PDFInfo
- Publication number
- US4108983A US4108983A US05/691,486 US69148676A US4108983A US 4108983 A US4108983 A US 4108983A US 69148676 A US69148676 A US 69148676A US 4108983 A US4108983 A US 4108983A
- Authority
- US
- United States
- Prior art keywords
- tumor
- virus
- cells
- vaccine
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 93
- 229960005486 vaccine Drugs 0.000 title claims abstract description 50
- 241000124008 Mammalia Species 0.000 title claims abstract description 38
- 230000003612 virological effect Effects 0.000 title claims abstract description 27
- 241000894007 species Species 0.000 title claims abstract description 26
- 230000008076 immune mechanism Effects 0.000 title claims description 12
- 230000004936 stimulating effect Effects 0.000 title claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 37
- 210000004027 cell Anatomy 0.000 claims abstract description 36
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 18
- 241000282414 Homo sapiens Species 0.000 claims abstract description 17
- 201000011510 cancer Diseases 0.000 claims abstract description 11
- 239000001963 growth medium Substances 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 15
- 230000001717 pathogenic effect Effects 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000004114 suspension culture Methods 0.000 claims description 7
- 230000002101 lytic effect Effects 0.000 claims description 5
- 230000002269 spontaneous effect Effects 0.000 claims description 5
- 230000002934 lysing effect Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 abstract description 31
- 208000007089 vaccinia Diseases 0.000 abstract description 31
- 230000028993 immune response Effects 0.000 abstract description 5
- 229940030325 tumor cell vaccine Drugs 0.000 abstract description 4
- 239000002955 immunomodulating agent Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010040914 Skin reaction Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 231100000430 skin reaction Toxicity 0.000 description 4
- 230000035483 skin reaction Effects 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 241000711386 Mumps virus Species 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000005951 type IV hypersensitivity Effects 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000724565 Chorella virus Species 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 101710151387 Serine protease 1 Proteins 0.000 description 1
- 102100032491 Serine protease 1 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710119665 Trypsin-1 Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 208000025188 carcinoma of pharynx Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940124954 vaccinia virus vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Definitions
- This invention relates to a vaccine capable of stimulating the immune response of a tumorous mammal against mammalian tumors, and, in particular, against species-specific mammalian tumors.
- Species-specific tumors are those which are specific to a particular species of mammal.
- the tumors may be induced, as can be the BALB/C male mouse peritoneal macrophage tumor, designated GMMSVI 2 , or may arise spontaneously as does colon cancer in humans.
- mice surviving the influenza oncolysis were noted to have developed post-viral oncolytic immunity and resisted rechallenge with the same tumor. Lindenmann, "Immunity to Transplantable Tumors Following Viral Oncolysis,” J. Immunology, Vol. 92, pp. 912-919 (1964).
- Numerous other viruses have been injected into mammals bearing tumors to effect in vivo viral oncolysis.
- the viruses worked with are vesicular stomatitis virus, reovirus, mumps virus and West Nile virus. This technique, though promising, is difficult to apply in practice since most oncolytic viruses described in the art are harmful to man, and attempts to directly infect "in vivo" human tumor cells have yielded unsatisfactory results.
- virus-lysed species-specific tumor cell vaccine (viral oncolysate) for mammals which is an active immunotherapeutic agent against species-specific mammalian tumors and which has no harmful effect on the mammal.
- virus-lysed tumor vaccine (viral oncolysate) which is an active immunotherapeutic agent against some human tumors in some patients.
- a vaccine for stimulating the immune mechanism of mammals to species-specific tumors which comprises a viral oncolysate of said tumor and a virus having a lytic action on the cells of said tumor, said virus being substantially less pathogenic for said mammal than is said tumor, and said viral oncolysate being the product of an in vitro oncolysis reaction.
- a vaccine for stimulating the immune mechanism of mammals to species-specific tumors prepared by removing tumor tissue from a mammal and growing cells of said tumor in a culture medium, infecting said cells with a virus capable of lysing said cells, said virus being less pathogenic for said mammal than is said tumor, and culturing said cells and virus until oncolysis occurs.
- I have developed a method of forming and using a vaccine capable of stimulating the immune mechanism of mammals to species-specific tumors, especially spontaneous malignant tumors, comprising infecting cells of the tumor in vitro with a virus which is substantially less pathogenic for said mammal than is said tumor, maintaining said virus infected cells under culture conditions until a viral oncolysate is formed, harvesting said oncolysate and administering said oncolysate to said mammal.
- the virus from which the oncolysate is formed be less pathogenic to the mammal than the tumor since little is gained if the mammal contracts the virion associated disease and succumbs to the disease. It is also necessary that the virus have a lytic action on tumor cells especially human tumor cells.
- vaccinia virus as the virus to be used for preparing the viral oncolysate
- my invention is not to be limited solely to the use of vaccinia virus, since any other live virus vaccine may be used so long as the virus is capable of lysing the tumor cells and is less pathogenic for the mammal into which the viral oncolysate is to be injected than the tumor cells themselves.
- tumor antigens are common to particular varieties of tumors, the vaccine is effective against tumors bearing the same antigen in the same species of mammal regardless of the particular host from which the initial tumor was obtained.
- the vaccine could be administered to patients whose tumors are inaccessible by standard surgical techniques.
- vaccine prepared from tumor cells obtained from one patient may be used to stimulate the immune mechanism of other patients having the same variety of tumor.
- mice have confirmed the safety and efficacy of the vaccine against species-specific tumors in animal models. In my experiments, there was no vaccine associated deaths and, furthermore, tumors failed to grow in animals prevaccinated with the vaccinia oncolysate.
- the vaccinia oncolysate may be prepared by infecting monolayers of tumor cells with 1 ml of live vaccinia virus and incubating for 96 hours. The oncolysate is then frozen and thawed three times and harvested by centrifugation of the lysed cellular debris at 39,100 g for 45 minutes at 0° C. The supernatent is removed and the pellet is resuspended in saline solution and homogenized to accomplish further cell destruction. The lysate is again centrifuged at 39,100 g and concentrated to effect a concentration of 1 ⁇ 10 6 vaccinia-lysed tumor cells per ml. This final concentrate constitutes a vaccinia oncolysate vaccine.
- the tumor cells be infected with the vaccinia virus while the tumor cells are in suspension because of the ease of keeping human tumor cells alive for short periods of time in suspension.
- the advantage of suspension culture is that the tumor used to prepare the viral vaccine may be difficult to grow in monolayer culture but easily grown for short periods in suspension.
- tumor cells taken from a patient are maintained in suspension, they may be easily infected with vaccinia virus and the oncolysate vaccine may be rapidly prepared and reinjected into the same patient or a different patient with the same type of tumor, i.e., colon cancer, gastric cancer, breast cancer, etc.
- mice All experiments were conducted in BALB/C male mice, 8-10 weeks old at the time of implantation of the tumor isografts. Each treatment and control group consisted of 6-8 mice, randomly distributed.
- GMMSVI 2 An SV40-transformed BALB/C male mouse peritoneal macrophage tumor, designated GMMSVI 2 , was used in all experiments. Tumor cells in doses ranging from 1 ⁇ 10 3 to 1 ⁇ 10 5 cells were injected subcutaneously into the left thigh of the mice.
- a standard vaccinia virus vaccine was obtained and cultured on WI-38 cells under standard conditions to increase the titer of the vaccine.
- Vaccine titers were determined on monolayers of WI-38 cells in Eagle's minimal essential medium (MEM), containing 3% fetal bovine serum (FBS).
- MEM Eagle's minimal essential medium
- FBS fetal bovine serum
- the vaccinia titer was increased to approximately 1 ⁇ 10 8 TCID 50 /ml.
- the virus was diluted 1:1000 in phosphate buffered saline (PBS) before injection.
- PBS phosphate buffered saline
- the vaccinia oncolysate was prepared by infecting monolayers of 1 ⁇ 10 6 GMMSVI 2 tumor cells with 1 ml of vaccinia virus (1 ⁇ 10 8 TCID 50 /ml) and incubating for 96 hours. The oncolysate was then frozen and thawed three times and harvested by centrifugation of the lysed cellular debris at 39,100 g for 45 minutes at 0° C. The pellet was then resuspended in 10 ml of Eagle's MEM without FBS and further cell destruction accomplished by using a Dounce homogenizer.
- This lysate was again centrifuged at 39,100 g and suspended in enough Eagle's MEM without FBS so as to effect a concentration of 1 ⁇ 10 6 vaccinia-lysed tumor cells per ml. This final concentration was the vaccinia oncolysate used in all the animal experiments. The vaccinia oncolysate was always injected subcutaneously into the right thigh. The quantity and the number of treatments are described hereinafter.
- mice Groups of 6-8 mice were injected subcutaneously into the right thigh with 0.3 ml of vaccinia oncolysate on day -17, -12, -7, -3, 0 and then received either 1 ⁇ 10 3 , 1 ⁇ 10 4 or 1 ⁇ 10 5 tumor cells subcutaneously into the left thigh on day 0. The mice were followed for approximately 60 days.
- mice prevaccinated with the vaccinia oncolysate prior to receiving tumor cells failed to develop tumors at the injection site as compared to controls.
- mice which were preimmunized with 0.3 ml of vaccinia virus (diluted with PBS to 1 ⁇ 10 5 TCID 50 /ml) subcutaneously into the right thigh and then immunized 1 ⁇ 10 4 tumor cells also failed to develop tumors as compared to controls.
- the following cancer patients were selected for treatment with the vaccinia oncolysate (vaccinia-lysed spontaneous tumor cell vaccine): (1) Cancer patients who had tumor resections and showed tumor metastasis to local and/or regional lymph nodes; (2) Patients submitted to radiation therapy for localized, unresectable disease; (3) Patients with disseminated disease treated by chemotherapy but considered terminal; (4) Patients with disease so far advanced that they were deemed untreatable by surgery, chemotherapy, or radiotherapy. All patients involved in these therapeutic trails gave informed consent by signing an authorization for the use of investigational therapy and showed a delayed hypersensitivity response to one of the common recall antigen skin tests used to gauge immunocompetence. An essential requirement was that cells from a tumor could be surgically obtained and grown in tissue culture, either in suspension or monolayer.
- Tumor tissue removed from the patient in the operating room was processed as follows: (1) Those portions of the tumor that are not necrotic, fatty or hemorrhagic are finely minced by scalpels and placed in Eagle's MEM with 20% FBS (fetal bovine serum) plus penicillin and gentamicin; (2) The minced tissue is placed in an Erlenmeyer flask with 30 ml of 0.25% trypsin 1% versene solution and stirred with a magnetic bar to effect a suspension of single cells; (3) Approximately 1 ⁇ 10 8 TCID 50 /ml of live vaccinia virus is used to infect 1 ⁇ 10 6 /ml of tumor cells in suspension; (4) The virus-tumor cell suspension is incubated for 96 hours at 37° C.
- FBS fetal bovine serum
- the vaccinia virus-lysed tumor cell suspension is spun at 39,100 g for 60 minutes at 0° C., the supernatant removed and the resulting pellet suspended in 10 ml of Eagle's MEM as the harvested oncolysate.
- the oncolysate is then collected in a sterile homogenizer tube, Dounce homogenized 20 times, centrifuged at 39,100 g for 60 minutes at 0° C., and the pellet resuspended in enough Eagle's MEM to effect a concentration of 1 ⁇ 10 6 vaccinia-lysed tumor cells per ml. These 1 ml aliquots will be frozen at 0° C. for use later.
- the vaccine may be stored at -70° C. ⁇ 10° C. for up to two years.
- the vaccinia oncolysate vaccine having a concentration of 1 ⁇ 10 6 vaccinia-lysed tumor cells per ml was injected in 1 ml doses. Each dose was divided and injected intradermally into the anterior thigh, upper arm and anterior thorax to stimulate regional lymph nodes. The oncolysate injections were given every two weeks for three months.
- Patient response to the vaccinia oncolysate immunotherapy was as follows: (1) 0/13 patients had adverse reactions; (2) 6/13 patients died; (3) 6/7 patients surviving had delayed hypersensitivity reactions at the vaccine injection sites; (4) 6/6 patients with positive skin reactions to the vaccine had elevated antibody titers; (5) 6/6 patients with positive skin reactions to the vaccine had previous positive reactions to common recall antigens; (6) 6/6 patients with positive skin reactions to the vaccine showed positive lymphocyte transformation to PHA; (7) 2/6 patients with positive skin reactions to the vaccine had reduction in tumor burden after immunotherapy.
- D. J. is a 46-year old woman who had an abdominal-perineal resection for Dukes B colon cancer.
- the patient developed a massive local perineal tumor recurrence that was refractory to radiotherapy. She then received four 1 ml dose treatments of the vaccinia oncolysate at two-week intervals. Each dose was divided and injected in proximity to regional lymph nodes with two injections being directly into the perineal tumor mass.
- the patient developed a significant delayed hypersensitivity response at the tumor site after the intratumor injections and subsequently there was a 50% reduction in the size of the tumor.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/691,486 US4108983A (en) | 1976-06-01 | 1976-06-01 | Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors |
NZ182891A NZ182891A (en) | 1976-06-01 | 1976-12-15 | Vaccine for stimulating the immune mechanism of mammals to species-specific tumours |
GB53723/76A GB1520200A (en) | 1976-06-01 | 1976-12-23 | Antitumour vaccines and their preparation |
CA269,176A CA1073814A (fr) | 1976-06-01 | 1977-01-05 | Vaccin et methode d'utilisation |
AU21735/77A AU511071B2 (en) | 1976-06-01 | 1977-01-27 | Vaccine against mammalian tumours |
DE19772705610 DE2705610A1 (de) | 1976-06-01 | 1977-02-10 | Vakzin und verfahren zu seiner herstellung |
FR7716547A FR2353641A1 (fr) | 1976-06-01 | 1977-05-31 | Vaccin anti-tumoral et son procede de preparation |
JP6391677A JPS52148617A (en) | 1976-06-01 | 1977-05-31 | Vaccine and production thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/691,486 US4108983A (en) | 1976-06-01 | 1976-06-01 | Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
US4108983A true US4108983A (en) | 1978-08-22 |
Family
ID=24776726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US05/691,486 Expired - Lifetime US4108983A (en) | 1976-06-01 | 1976-06-01 | Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors |
Country Status (8)
Country | Link |
---|---|
US (1) | US4108983A (fr) |
JP (1) | JPS52148617A (fr) |
AU (1) | AU511071B2 (fr) |
CA (1) | CA1073814A (fr) |
DE (1) | DE2705610A1 (fr) |
FR (1) | FR2353641A1 (fr) |
GB (1) | GB1520200A (fr) |
NZ (1) | NZ182891A (fr) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652522A (en) * | 1983-07-05 | 1987-03-24 | The University Of Pennsylvania | Continuous lymphocyte cell lines, their production and use |
US5124148A (en) * | 1988-04-27 | 1992-06-23 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
US5215745A (en) * | 1988-04-27 | 1993-06-01 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
US5290551A (en) * | 1990-05-08 | 1994-03-01 | Thomas Jefferson University | Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten |
US5635188A (en) * | 1987-04-23 | 1997-06-03 | Bystryn; Jean-Claude | Anti-cancer vaccine |
US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US6338853B1 (en) | 1987-04-23 | 2002-01-15 | Jean-Claude Bystryn | Anti-cancer vaccine |
US6565831B1 (en) | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US6586411B1 (en) | 2000-08-16 | 2003-07-01 | Mayo Foundation For Medical Education And Research | System for monitoring the location of transgenes |
US20030165465A1 (en) * | 1997-10-09 | 2003-09-04 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US6896881B1 (en) | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
US7015205B1 (en) | 1999-10-18 | 2006-03-21 | St. Vincent's Hospital And Medical Center Of New York | Melanoma vaccine and methods of making and using same |
US7056689B1 (en) | 1993-04-30 | 2006-06-06 | Wellstat Biologics Corporation | Methods of treating and detecting cancer using viruses |
US7118740B1 (en) | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
US7229628B1 (en) * | 1995-07-25 | 2007-06-12 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US20070190032A1 (en) * | 2006-02-13 | 2007-08-16 | Oncolytics Biotech Inc. | Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy |
US20080057037A1 (en) * | 1997-10-09 | 2008-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US20090081161A1 (en) * | 1997-10-09 | 2009-03-26 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
US7585512B1 (en) | 1990-05-08 | 2009-09-08 | Thomas Jefferson University | Composition and method of using tumor cells |
US9428736B2 (en) | 2010-09-02 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
US9623096B2 (en) | 2011-11-09 | 2017-04-18 | Celverum Inc. | Virally infected hematopoietic cells and uses thereof |
US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0037441B1 (fr) * | 1980-03-10 | 1984-05-09 | Seiji Arakawa | Compositions pharmaceutiques utilisables comme immunostimulant cellulaire et comme agent anti-tumeur, procédé de préparation et microorganisme utilisé |
JPS5835121A (ja) * | 1981-08-20 | 1983-03-01 | ビラス・ヴィー・リクハイト | 免疫刺激性補助剤からなる抗原及び免疫療法におけるその使用 |
JPS6038328A (ja) * | 1983-08-11 | 1985-02-27 | Handai Biseibutsubiyou Kenkyukai | 抗腫瘍免疫誘導の増強法 |
AU5275290A (en) * | 1989-04-11 | 1990-11-05 | Board Of Regents, The University Of Texas System | Antitumor preparation obtained following oncolysate treatment |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3553312A (en) * | 1968-02-26 | 1971-01-05 | Flow Lab | Process for producing rubella-virus hemagglutinating antigen |
-
1976
- 1976-06-01 US US05/691,486 patent/US4108983A/en not_active Expired - Lifetime
- 1976-12-15 NZ NZ182891A patent/NZ182891A/xx unknown
- 1976-12-23 GB GB53723/76A patent/GB1520200A/en not_active Expired
-
1977
- 1977-01-05 CA CA269,176A patent/CA1073814A/fr not_active Expired
- 1977-01-27 AU AU21735/77A patent/AU511071B2/en not_active Expired
- 1977-02-10 DE DE19772705610 patent/DE2705610A1/de active Granted
- 1977-05-31 JP JP6391677A patent/JPS52148617A/ja active Pending
- 1977-05-31 FR FR7716547A patent/FR2353641A1/fr active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3553312A (en) * | 1968-02-26 | 1971-01-05 | Flow Lab | Process for producing rubella-virus hemagglutinating antigen |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652522A (en) * | 1983-07-05 | 1987-03-24 | The University Of Pennsylvania | Continuous lymphocyte cell lines, their production and use |
US5635188A (en) * | 1987-04-23 | 1997-06-03 | Bystryn; Jean-Claude | Anti-cancer vaccine |
US6338853B1 (en) | 1987-04-23 | 2002-01-15 | Jean-Claude Bystryn | Anti-cancer vaccine |
US5124148A (en) * | 1988-04-27 | 1992-06-23 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
US5215745A (en) * | 1988-04-27 | 1993-06-01 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
US5290551A (en) * | 1990-05-08 | 1994-03-01 | Thomas Jefferson University | Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten |
US7585512B1 (en) | 1990-05-08 | 2009-09-08 | Thomas Jefferson University | Composition and method of using tumor cells |
US7736640B2 (en) | 1993-04-30 | 2010-06-15 | Wellstat Biologics Corporation | Methods of treating and detecting cancer using viruses |
US20060216310A1 (en) * | 1993-04-30 | 2006-09-28 | Wellstat Biologics Corporation | Methods of treating and detecting cancer using viruses |
US7056689B1 (en) | 1993-04-30 | 2006-06-06 | Wellstat Biologics Corporation | Methods of treating and detecting cancer using viruses |
US7229628B1 (en) * | 1995-07-25 | 2007-06-12 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6261555B1 (en) | 1997-08-13 | 2001-07-17 | Oncolytics Biotech, Inc. | Reovirus for the treatment of neoplasia |
US20050123513A1 (en) * | 1997-08-13 | 2005-06-09 | Oncolytics Biotech Inc., A Canada Corporation | Reovirus for the treatment of neoplasia |
US7708987B2 (en) | 1997-08-13 | 2010-05-04 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US6455038B1 (en) | 1997-08-13 | 2002-09-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US20030215443A1 (en) * | 1997-08-13 | 2003-11-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US6344195B1 (en) | 1997-08-13 | 2002-02-05 | Oncolytics Biotech, Inc. | Reovirus for the treatment of neoplasia |
US20040265271A1 (en) * | 1997-08-13 | 2004-12-30 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US20090110665A1 (en) * | 1997-08-13 | 2009-04-30 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US20090098089A1 (en) * | 1997-08-13 | 2009-04-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6576234B2 (en) | 1997-08-13 | 2003-06-10 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US7476382B2 (en) | 1997-08-13 | 2009-01-13 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US7452723B2 (en) | 1997-08-13 | 2008-11-18 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US7014847B2 (en) | 1997-08-13 | 2006-03-21 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US20060073166A1 (en) * | 1997-08-13 | 2006-04-06 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US20080075729A1 (en) * | 1997-08-13 | 2008-03-27 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US7300650B2 (en) | 1997-08-13 | 2007-11-27 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US20030165465A1 (en) * | 1997-10-09 | 2003-09-04 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US20090081161A1 (en) * | 1997-10-09 | 2009-03-26 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
US20080057037A1 (en) * | 1997-10-09 | 2008-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US8105578B2 (en) | 1997-10-09 | 2012-01-31 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
US8043612B2 (en) * | 1997-10-09 | 2011-10-25 | Wellstat Biologics Corporation | Infection and treatment of neoplasms with vesicular stomatitis virus |
US8071087B2 (en) | 1999-02-24 | 2011-12-06 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US8066985B2 (en) | 1999-02-24 | 2011-11-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US7374752B2 (en) | 1999-02-24 | 2008-05-20 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US20110014155A1 (en) * | 1999-02-24 | 2011-01-20 | Oncolytics Biotech Inc. | Reovirus for the Treatment of Cellular Proliferative Disorders |
US6565831B1 (en) | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US8709443B2 (en) | 1999-02-24 | 2014-04-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US20050063954A1 (en) * | 1999-02-24 | 2005-03-24 | Oncolytics Biotech Inc., A Canada Corporation | Reovirus for the treatment of cellular proliferative disorders |
US20090117082A1 (en) * | 1999-02-24 | 2009-05-07 | Oncolytics Biotech Inc. | Reovirus for the Treatment of Cellular Proliferative Disorders |
US6811775B2 (en) | 1999-02-24 | 2004-11-02 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US20050214218A1 (en) * | 1999-09-24 | 2005-09-29 | Mayo Foundation For Medical Education And Research, A Minnesota Corporation | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
US6896881B1 (en) | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
US7015205B1 (en) | 1999-10-18 | 2006-03-21 | St. Vincent's Hospital And Medical Center Of New York | Melanoma vaccine and methods of making and using same |
US7982022B2 (en) | 2000-08-16 | 2011-07-19 | Mayo Foundation For Medical Education And Research | System for monitoring the location of transgenes |
US7645865B2 (en) | 2000-08-16 | 2010-01-12 | Mayo Foundation For Medical Education And Research | System for monitoring the location of transgenes |
US20100099182A1 (en) * | 2000-08-16 | 2010-04-22 | Mayo Foundation For Medical Education And Research | System for monitoring the location of transgenes |
US6586411B1 (en) | 2000-08-16 | 2003-07-01 | Mayo Foundation For Medical Education And Research | System for monitoring the location of transgenes |
US20090004149A1 (en) * | 2000-09-22 | 2009-01-01 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
US7393527B2 (en) | 2000-09-22 | 2008-07-01 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
US7670598B2 (en) | 2000-09-22 | 2010-03-02 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
US7118740B1 (en) | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
US20070071771A1 (en) * | 2000-09-22 | 2007-03-29 | Mayo Foundation For Medical Education And Research, A Minnesota Corporation | Method for limiting the growth of cancer cells using an attenuated measles virus |
US20070190032A1 (en) * | 2006-02-13 | 2007-08-16 | Oncolytics Biotech Inc. | Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy |
US9428736B2 (en) | 2010-09-02 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
US10752666B2 (en) | 2010-09-02 | 2020-08-25 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
US11634469B2 (en) | 2010-09-02 | 2023-04-25 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
US9623096B2 (en) | 2011-11-09 | 2017-04-18 | Celverum Inc. | Virally infected hematopoietic cells and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
FR2353641A1 (fr) | 1977-12-30 |
FR2353641B1 (fr) | 1980-07-18 |
AU511071B2 (en) | 1980-07-24 |
NZ182891A (en) | 1984-03-30 |
DE2705610C2 (fr) | 1989-08-03 |
DE2705610A1 (de) | 1977-12-15 |
GB1520200A (en) | 1978-08-02 |
CA1073814A (fr) | 1980-03-18 |
JPS52148617A (en) | 1977-12-10 |
AU2173577A (en) | 1978-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4108983A (en) | Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors | |
US5273745A (en) | Virus-modified tumor vaccines for immunotherapy of tumor metastases | |
Wallack et al. | A new approach in specific, active immunotherapy | |
US20200261509A1 (en) | Vaccine compositions and methods | |
US11833173B2 (en) | Th1 vaccination priming for active immunotherapy | |
US8802113B2 (en) | Extracellular matrix cancer vaccine adjuvant | |
BRPI0618050A2 (pt) | uso de peptìdeo egfrviii e vacina antitumor em combinação com outros componentes para o tratamento de tumor | |
EP3456350A1 (fr) | Adjuvant immunologique composite gel d'hydroxyde d'aluminium-chlorure de sodium, son procédé de préparation et ses applications | |
US8778360B2 (en) | Extracellular matrix cancer vaccine adjuvant | |
Ollila et al. | Overview of melanoma vaccines: active specific immunotherapy for melanoma patients | |
Prager et al. | Immunization with chemically modified lymphoma cells | |
Parkman | Tumor hybrid cells: an immunotherapeutic agent | |
Lamm et al. | Keyhole-limpet haemacyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma | |
McCarthy et al. | Immunotherapy of malignant melanoma. A clinical trial | |
US5762931A (en) | Anti-cancer utility of HCG vaccines | |
US20210154296A1 (en) | Vaccine or immunotherapeutic agent composition containing photothermally treated cell lysates as active ingredients | |
WO2004096244A1 (fr) | Procede de preparation d'un vaccin pour induire une activite antitumorale et composition pharmaceutique le comprenant | |
Reintgen et al. | Experimental trials of immunotherapy for malignant melanoma | |
KR101523584B1 (ko) | 선천면역 및 획득면역능을 갖는 종양 백신 및 이를유효성분으로 함유하는 약제학적 조성물 | |
Barber et al. | Immunotherapy and immunopotentiation | |
KR20060116850A (ko) | 수지상 세포의 종양내 전달 | |
WO1994015633A1 (fr) | Effet anticancereux de vaccins contre la gonadotrophine chorionique humaine |